DK382989D0 - Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf - Google Patents

Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf

Info

Publication number
DK382989D0
DK382989D0 DK382989A DK382989A DK382989D0 DK 382989 D0 DK382989 D0 DK 382989D0 DK 382989 A DK382989 A DK 382989A DK 382989 A DK382989 A DK 382989A DK 382989 D0 DK382989 D0 DK 382989D0
Authority
DK
Denmark
Prior art keywords
cytotoxic
antibodies
procedures
producing
bonded
Prior art date
Application number
DK382989A
Other languages
English (en)
Other versions
DK382989A (da
Inventor
George Joseph Cullinan
Bennett Coleman Laguzza
William Leonard Scott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK382989D0 publication Critical patent/DK382989D0/da
Publication of DK382989A publication Critical patent/DK382989A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44Antibodies bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK382989A 1988-08-08 1989-08-04 Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf DK382989A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/230,084 US5006652A (en) 1988-08-08 1988-08-08 Intermediates for antibody-vinca drug conjugates

Publications (2)

Publication Number Publication Date
DK382989D0 true DK382989D0 (da) 1989-08-04
DK382989A DK382989A (da) 1990-02-09

Family

ID=22863896

Family Applications (1)

Application Number Title Priority Date Filing Date
DK382989A DK382989A (da) 1988-08-08 1989-08-04 Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf

Country Status (15)

Country Link
US (1) US5006652A (da)
EP (1) EP0354728A3 (da)
JP (1) JPH02131499A (da)
KR (1) KR900002804A (da)
CN (1) CN1040205A (da)
AR (1) AR245368A1 (da)
AU (1) AU619329B2 (da)
DK (1) DK382989A (da)
HU (1) HU206377B (da)
IL (1) IL91182A0 (da)
MX (1) MX164971B (da)
NZ (1) NZ230200A (da)
PH (1) PH27351A (da)
PT (1) PT91372A (da)
ZA (1) ZA895908B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
AU633867B2 (en) * 1989-02-02 1993-02-11 Eli Lilly And Company Delivery of cytotoxic agents
US5272253A (en) * 1991-07-01 1993-12-21 Eli Lilly And Company Cluster conjugates of drugs with antibodies
GR1001459B (el) * 1992-10-08 1993-12-30 Lilly Co Eli Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
ES2049656B1 (es) * 1992-10-08 1994-11-16 Lilly Co Eli Grupos de conjugados de farmacos con anticuerpos.
US5773001A (en) * 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
JP2004536027A (ja) 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化/ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー/ポリマー、および関連する組成物および使用方法
ATE427948T1 (de) * 2001-04-24 2009-04-15 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
CA2484640C (en) * 2002-05-15 2012-01-17 Endocyte, Inc. Vitamin-mitomycin conjugates
WO2004069159A2 (en) 2003-01-27 2004-08-19 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
JP5289935B2 (ja) * 2005-03-16 2013-09-11 エンドサイト,インコーポレイテッド プテロイン酸およびその結合体の合成と精製
ES2468240T3 (es) * 2005-08-19 2014-06-16 Endocyte, Inc. Conjugados de ligando de múltiples fármacos
US20080280937A1 (en) * 2005-08-19 2008-11-13 Christopher Paul Leamon Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
CN101678124A (zh) * 2007-03-14 2010-03-24 恩多塞特公司 结合配体连接的微管溶素递药缀合物
EP3569251A1 (en) 2007-06-25 2019-11-20 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CA2703491C (en) * 2007-10-25 2017-06-13 Endocyte, Inc. Tubulysins and processes for preparing
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
AU2013331440A1 (en) 2012-10-16 2015-04-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
MX368258B (es) 2013-03-15 2019-09-25 Zymeworks Inc Compuestos citotoxicos y antimitoticos y metodos de uso de los mismos.
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
HUE057768T2 (hu) 2014-09-17 2022-06-28 Zymeworks Inc Citotoxikus és antimitotikus vegyületek és azok alkalmazásának módszerei

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
FI820020L (fi) * 1981-01-12 1982-07-13 Lilly Industries Ltd Immunoglobulinkonjugater
US4631190A (en) * 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
CA1203164A (en) * 1982-03-09 1986-04-15 Thomas J. Mckearn Antibody conjugates
DE3482444D1 (de) * 1983-03-30 1990-07-19 Lilly Industries Ltd Immunoglobulinkonjugate.
GR81790B (da) * 1983-04-29 1984-12-12 Omnichem Sa
LU86157A1 (fr) * 1985-11-12 1987-06-26 Omnichem Sa Nouveau procede de fabrication de conjugues de la vinblastine et de ses derives
US4675400A (en) * 1985-06-17 1987-06-23 Eli Lilly And Company Bifunctional derivatives of 4-desacetyl indole-dihydroindole alkaloids
EP0232693A3 (fr) * 1985-12-16 1988-04-06 La Region Wallonne Conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques les contenant
GB8610551D0 (en) * 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
IL82579A0 (en) * 1986-05-27 1987-11-30 Lilly Co Eli Immunoglobulin conjugates
US4997913A (en) * 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
FR2610198B1 (fr) * 1987-02-03 1990-06-15 Ire Celltarg Sa Conjugues d'hydrazide d'alcaloide de vinca lie a une immunoglobuline, procede de preparation et compositions pharmaceutiques en comprenant
ZA89524B (en) * 1988-01-27 1990-09-26 Lilly Co Eli Antibody conjugates

Also Published As

Publication number Publication date
IL91182A0 (en) 1990-03-19
EP0354728A3 (en) 1991-04-10
US5006652A (en) 1991-04-09
DK382989A (da) 1990-02-09
KR900002804A (ko) 1990-03-23
MX164971B (es) 1992-10-09
EP0354728A2 (en) 1990-02-14
ZA895908B (en) 1991-04-24
CN1040205A (zh) 1990-03-07
AU3933989A (en) 1990-02-08
AU619329B2 (en) 1992-01-23
HUT50488A (en) 1990-02-28
NZ230200A (en) 1991-11-26
AR245368A1 (es) 1994-01-31
PH27351A (en) 1993-06-21
HU206377B (en) 1992-10-28
JPH02131499A (ja) 1990-05-21
PT91372A (pt) 1990-03-08

Similar Documents

Publication Publication Date Title
DK382989A (da) Cytotoxiske vinca-konjugater bundet til antistoffer og fremgangsmaade til fremstilling deraf
DK382889A (da) Konjugater af antistoffer og cytotoxiske methotrexat-forbindelser og fremgangsmaade til fremstilling af saadanne konjugater
NO893464L (no) Fremgangsmaate for aa anbringe et legeme av formminnemateriale i et hulrom.
DK194589D0 (da) Partikelformede vaskemidler og fremgangsmaade til fremstilling deraf
AU4807185A (en) Antibody therapeutic agent conjugates
DK251188A (da) Goedningsmiddel og fremgangsmaade til fremstilling deraf
DK665187D0 (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling heraf
DK260687A (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling deraf
DK556689A (da) Antistof-konjugater, fremgangsmaade til fremstilling heraf og farmaceutiske midler indeholdende disse
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
DK251288A (da) Goedningsmiddel og fremgangsmaade til fremstilling deraf
DK397788D0 (da) Polyarylalkan-oligomer-praeparater og fremgangsmaade til fremstilling deraf
DK32989A (da) Immunoglobulin-konjugater og fremgangsmaade til fremstilling deraf
DK131588A (da) Immunoglobulinkonjugater
AU590731B2 (en) Estriol-3-sulfate protein conjugates and antibodies thereto
DK129689D0 (da) Ifosfamid-mesna-lyofilisat og fremgangsmaade til fremstilling deraf
AU5217890A (en) Monoclonal antibodies in vaccine formulations
DK240289A (da) Cellulose-kompositmateriale og fremgangsmaade til fremstilling deraf
ATE68974T1 (de) Therapeutische antikoerpermittelkonjugate.
DK287288D0 (da) Polypeptid og fremgangmaade til fremstilling deraf
DK319188A (da) Glycerolacetalaminoacylat og fremgangsmaade til fremstilling deraf
KR900000142U (ko) 목걸이 결합구
GB8705550D0 (en) Monoclonal antibodies to urokinase
DK594488D0 (da) Plantegummimateriale og fremgangsmaade til fremstilling af samme
IE861508L (en) Antibody conjugates

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment